Enhancing the delivery of anti retroviral drug "saquinavir" across the blood brain barrier using nanoparticles

Supriya D. Mahajan, Indrajit Roy, GaiXia Xu, Ken Tye Yong, Hong Ding, Ravikumar Aalinkeel, Jessica L. Reynolds, Donald E. Sykes, Bindukumar B. Nair, Elaine Lin, Paras N. Prasad, Stanley A. Schwartz

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Antiretroviral drugs are ineffective at treating viral infection in the brain because they cannot freely diffuse across the blood-brain barrier (BBB). Therefore, HIV-1 viral replication persists in the central nervous system (CNS) and continues to augment the neuropathogenesis process. Nanotechnology can play a pivotal role in HIV-1 therapeutics as it can increase drug solubility, enhance systemic bioavailability, and at the same time offer multifunctionality. Moreover, following conjugation with transferrin (Tf), these drug-loaded nanoformulations can permeate across biological barriers such as the blood brain barrier (BBB) via a receptor mediated transport mechanism. In the current study, we have stably incorporated the antiviral drug, Saquinavir, within Tf-conjugated quantum rods (QRs), which are novel nanoparticles with unique optical properties. We have evaluated the transversing ability of the QR-Tf-Saquinavir nanoformulation across an in vitro model of BBB. In addition, we have analyzed the subsequent antiviral efficacy of this targeted nanoformulation in HIV-1 infected peripheral blood mononuclear cells (PBMCs), which are cultured on the basolateral end of the in vitro BBB model. Our results show a significant uptake of QR-Tf-Saquinavir by brain microvascular endothelial cells (BMVECs), which constitute the BBB. In addition, we observed a significant enhancement in the transversing capability of QR-Tf-Saquinavir across the BBB, along with a marked decrease in HIV-1 viral replication in the PBMCs. These observations indicate that drug-loaded nanoparticles can deliver therapeutics across the BBB. These results highlight the potential of this nanoformulation in the treatment of Neuro-AIDS and other neurological disorders.

Original languageEnglish (US)
Pages (from-to)396-404
Number of pages9
JournalCurrent HIV Research
Volume8
Issue number5
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Saquinavir
Blood-Brain Barrier
Nanoparticles
Transferrin
HIV-1
Pharmaceutical Preparations
Antiviral Agents
Blood Cells
Nanotechnology
Brain
Virus Diseases
Nervous System Diseases
Solubility
Biological Availability
Acquired Immunodeficiency Syndrome
Central Nervous System
Endothelial Cells
Therapeutics

Keywords

  • Antiretroviral drugs
  • Blood brain barrier
  • Hiv-1
  • Multimodal nanoparticles and bioconjugation
  • Protease inhibitor
  • Quantum rods (qr)
  • Saquinavir
  • Transferrin receptor

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Mahajan, S. D., Roy, I., Xu, G., Yong, K. T., Ding, H., Aalinkeel, R., ... Schwartz, S. A. (2010). Enhancing the delivery of anti retroviral drug "saquinavir" across the blood brain barrier using nanoparticles. Current HIV Research, 8(5), 396-404. https://doi.org/10.2174/157016210791330356

Enhancing the delivery of anti retroviral drug "saquinavir" across the blood brain barrier using nanoparticles. / Mahajan, Supriya D.; Roy, Indrajit; Xu, GaiXia; Yong, Ken Tye; Ding, Hong; Aalinkeel, Ravikumar; Reynolds, Jessica L.; Sykes, Donald E.; Nair, Bindukumar B.; Lin, Elaine; Prasad, Paras N.; Schwartz, Stanley A.

In: Current HIV Research, Vol. 8, No. 5, 2010, p. 396-404.

Research output: Contribution to journalArticle

Mahajan, SD, Roy, I, Xu, G, Yong, KT, Ding, H, Aalinkeel, R, Reynolds, JL, Sykes, DE, Nair, BB, Lin, E, Prasad, PN & Schwartz, SA 2010, 'Enhancing the delivery of anti retroviral drug "saquinavir" across the blood brain barrier using nanoparticles', Current HIV Research, vol. 8, no. 5, pp. 396-404. https://doi.org/10.2174/157016210791330356
Mahajan, Supriya D. ; Roy, Indrajit ; Xu, GaiXia ; Yong, Ken Tye ; Ding, Hong ; Aalinkeel, Ravikumar ; Reynolds, Jessica L. ; Sykes, Donald E. ; Nair, Bindukumar B. ; Lin, Elaine ; Prasad, Paras N. ; Schwartz, Stanley A. / Enhancing the delivery of anti retroviral drug "saquinavir" across the blood brain barrier using nanoparticles. In: Current HIV Research. 2010 ; Vol. 8, No. 5. pp. 396-404.
@article{48975dbea8e443edaa4239cbb7ab6ff3,
title = "Enhancing the delivery of anti retroviral drug {"}saquinavir{"} across the blood brain barrier using nanoparticles",
abstract = "Antiretroviral drugs are ineffective at treating viral infection in the brain because they cannot freely diffuse across the blood-brain barrier (BBB). Therefore, HIV-1 viral replication persists in the central nervous system (CNS) and continues to augment the neuropathogenesis process. Nanotechnology can play a pivotal role in HIV-1 therapeutics as it can increase drug solubility, enhance systemic bioavailability, and at the same time offer multifunctionality. Moreover, following conjugation with transferrin (Tf), these drug-loaded nanoformulations can permeate across biological barriers such as the blood brain barrier (BBB) via a receptor mediated transport mechanism. In the current study, we have stably incorporated the antiviral drug, Saquinavir, within Tf-conjugated quantum rods (QRs), which are novel nanoparticles with unique optical properties. We have evaluated the transversing ability of the QR-Tf-Saquinavir nanoformulation across an in vitro model of BBB. In addition, we have analyzed the subsequent antiviral efficacy of this targeted nanoformulation in HIV-1 infected peripheral blood mononuclear cells (PBMCs), which are cultured on the basolateral end of the in vitro BBB model. Our results show a significant uptake of QR-Tf-Saquinavir by brain microvascular endothelial cells (BMVECs), which constitute the BBB. In addition, we observed a significant enhancement in the transversing capability of QR-Tf-Saquinavir across the BBB, along with a marked decrease in HIV-1 viral replication in the PBMCs. These observations indicate that drug-loaded nanoparticles can deliver therapeutics across the BBB. These results highlight the potential of this nanoformulation in the treatment of Neuro-AIDS and other neurological disorders.",
keywords = "Antiretroviral drugs, Blood brain barrier, Hiv-1, Multimodal nanoparticles and bioconjugation, Protease inhibitor, Quantum rods (qr), Saquinavir, Transferrin receptor",
author = "Mahajan, {Supriya D.} and Indrajit Roy and GaiXia Xu and Yong, {Ken Tye} and Hong Ding and Ravikumar Aalinkeel and Reynolds, {Jessica L.} and Sykes, {Donald E.} and Nair, {Bindukumar B.} and Elaine Lin and Prasad, {Paras N.} and Schwartz, {Stanley A.}",
year = "2010",
doi = "10.2174/157016210791330356",
language = "English (US)",
volume = "8",
pages = "396--404",
journal = "Current HIV Research",
issn = "1570-162X",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Enhancing the delivery of anti retroviral drug "saquinavir" across the blood brain barrier using nanoparticles

AU - Mahajan, Supriya D.

AU - Roy, Indrajit

AU - Xu, GaiXia

AU - Yong, Ken Tye

AU - Ding, Hong

AU - Aalinkeel, Ravikumar

AU - Reynolds, Jessica L.

AU - Sykes, Donald E.

AU - Nair, Bindukumar B.

AU - Lin, Elaine

AU - Prasad, Paras N.

AU - Schwartz, Stanley A.

PY - 2010

Y1 - 2010

N2 - Antiretroviral drugs are ineffective at treating viral infection in the brain because they cannot freely diffuse across the blood-brain barrier (BBB). Therefore, HIV-1 viral replication persists in the central nervous system (CNS) and continues to augment the neuropathogenesis process. Nanotechnology can play a pivotal role in HIV-1 therapeutics as it can increase drug solubility, enhance systemic bioavailability, and at the same time offer multifunctionality. Moreover, following conjugation with transferrin (Tf), these drug-loaded nanoformulations can permeate across biological barriers such as the blood brain barrier (BBB) via a receptor mediated transport mechanism. In the current study, we have stably incorporated the antiviral drug, Saquinavir, within Tf-conjugated quantum rods (QRs), which are novel nanoparticles with unique optical properties. We have evaluated the transversing ability of the QR-Tf-Saquinavir nanoformulation across an in vitro model of BBB. In addition, we have analyzed the subsequent antiviral efficacy of this targeted nanoformulation in HIV-1 infected peripheral blood mononuclear cells (PBMCs), which are cultured on the basolateral end of the in vitro BBB model. Our results show a significant uptake of QR-Tf-Saquinavir by brain microvascular endothelial cells (BMVECs), which constitute the BBB. In addition, we observed a significant enhancement in the transversing capability of QR-Tf-Saquinavir across the BBB, along with a marked decrease in HIV-1 viral replication in the PBMCs. These observations indicate that drug-loaded nanoparticles can deliver therapeutics across the BBB. These results highlight the potential of this nanoformulation in the treatment of Neuro-AIDS and other neurological disorders.

AB - Antiretroviral drugs are ineffective at treating viral infection in the brain because they cannot freely diffuse across the blood-brain barrier (BBB). Therefore, HIV-1 viral replication persists in the central nervous system (CNS) and continues to augment the neuropathogenesis process. Nanotechnology can play a pivotal role in HIV-1 therapeutics as it can increase drug solubility, enhance systemic bioavailability, and at the same time offer multifunctionality. Moreover, following conjugation with transferrin (Tf), these drug-loaded nanoformulations can permeate across biological barriers such as the blood brain barrier (BBB) via a receptor mediated transport mechanism. In the current study, we have stably incorporated the antiviral drug, Saquinavir, within Tf-conjugated quantum rods (QRs), which are novel nanoparticles with unique optical properties. We have evaluated the transversing ability of the QR-Tf-Saquinavir nanoformulation across an in vitro model of BBB. In addition, we have analyzed the subsequent antiviral efficacy of this targeted nanoformulation in HIV-1 infected peripheral blood mononuclear cells (PBMCs), which are cultured on the basolateral end of the in vitro BBB model. Our results show a significant uptake of QR-Tf-Saquinavir by brain microvascular endothelial cells (BMVECs), which constitute the BBB. In addition, we observed a significant enhancement in the transversing capability of QR-Tf-Saquinavir across the BBB, along with a marked decrease in HIV-1 viral replication in the PBMCs. These observations indicate that drug-loaded nanoparticles can deliver therapeutics across the BBB. These results highlight the potential of this nanoformulation in the treatment of Neuro-AIDS and other neurological disorders.

KW - Antiretroviral drugs

KW - Blood brain barrier

KW - Hiv-1

KW - Multimodal nanoparticles and bioconjugation

KW - Protease inhibitor

KW - Quantum rods (qr)

KW - Saquinavir

KW - Transferrin receptor

UR - http://www.scopus.com/inward/record.url?scp=77954704134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954704134&partnerID=8YFLogxK

U2 - 10.2174/157016210791330356

DO - 10.2174/157016210791330356

M3 - Article

C2 - 20426757

AN - SCOPUS:77954704134

VL - 8

SP - 396

EP - 404

JO - Current HIV Research

JF - Current HIV Research

SN - 1570-162X

IS - 5

ER -